Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

629
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
629
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

7.8K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
7.8K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

688
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
688
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

70
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
70

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

DNA-Based Nanoprobes for Fluorescence K+ Sensing in Neural Systems.

bioRxiv : the preprint server for biology·2026
Same author

Incorporating Teamwork Strategies for Internal Medicine Residents in Training to Mitigate Hospital Utilization for High-Risk Patients.

Rhode Island medical journal (2013)·2026
Same author

The Merits of Team-based Primary Care for the Underserved.

Rhode Island medical journal (2013)·2024
Same author

Outcomes of a pharmacist-managed clinic for underserved persons with unmanaged type 2 diabetes mellitus.

Journal of pharmacy practice and research : official journal of the Society of Hospital Pharmacists of Australia·2023
Same author

Development and validation of the Tool for Pharmacists to Predict 30-day hospital readmission in patients with Heart Failure (ToPP-HF).

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2021
Same author

Impact of antibiotic choice on readmission in adults experiencing an acute COPD exacerbation.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2020

Related Experiment Video

Updated: Mar 11, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.3K

Targeted Immunomodulatory Therapy: An Overview.

Ashley L Lefebvre1, Laura McAuliffe2

  • 1Clinical Pharmacist Specialist, Ambulatory Care, Department of Pharmacy, Rhode Island Hospital, Providence, RI.

Rhode Island Medical Journal (2013)
|December 1, 2016
PubMed
Summary
This summary is machine-generated.

Targeted therapies like monoclonal antibodies offer new ways to manage autoimmune diseases by focusing on specific immune pathways. More treatment options are emerging for these complex conditions.

Keywords:
biologic response modifiersimmunomodulatory therapymonoclonal antibodies

More Related Videos

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.8K
In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
08:02

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

6.0K

Related Experiment Videos

Last Updated: Mar 11, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.3K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.8K
In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
08:02

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

6.0K

Area of Science:

  • Immunology
  • Pharmacology
  • Autoimmune Diseases

Background:

  • Biologic response modifiers, including monoclonal antibodies, have advanced targeted drug therapy.
  • Management of autoimmune diseases has benefited from these targeted approaches.
  • Several immune pathways are being explored for novel immunomodulatory therapies.

Purpose of the Study:

  • To review the development and application of targeted immunomodulatory therapies for autoimmune diseases.
  • To highlight the role of monoclonal antibodies and other biologic response modifiers.
  • To discuss emerging targeted therapies in the pipeline.

Main Methods:

  • Review of immune pathways targeted in therapy development.
  • Identification of therapies targeting cytokines (e.g., TNF-alpha, interleukins), integrins, B-cells, and co-stimulation.
  • Analysis of current and pipeline targeted treatments.

Main Results:

  • Targeted therapies have shown efficacy in managing autoimmune conditions.
  • Exploitation of immune pathways has led to diverse treatment strategies.
  • New targeted therapies are continually being developed.

Conclusions:

  • Monoclonal antibodies and biologic response modifiers represent significant advancements in autoimmune disease management.
  • Targeting specific immune pathways offers personalized treatment options.
  • The pipeline of new targeted therapies promises expanded treatment choices for patients.